MoonLake ImmunotherapeuticsMLTX
Market cap
$895.64M
P/E ratio
| 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Depreciation & amortization | - | - | - | - | 1 |
| Stock-based compensation | - | - | 10 | 7 | 7 |
| Cash from operations | -316,692 | -611,071 | -55,893,900 | -42,778,167 | -116,587,263 |
| Capital expenditures | - | - | -16,009 | -284,634 | -519,520 |
| Cash from investing | -115,000,000 | - | -32,340,593 | -25,184,324 | -205,595,299 |
| Repurchases of common stock | - | - | - | - | 50 |
| Cash from financing | 117 | -58,063 | 120 | 480 | 51 |
| Free cash flow | - | - |